

CytoSorbents™

Working to save lives **together.**

NASDAQ: CTSO

Jefferies Global Healthcare Conference

November 18, 2025

CytoSorbents™

Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results, the restructuring of our direct sales team and strategy in Germany, our ability to resolve deficiencies in the FDA denial letter and the Health Canada Notice of Refusal and/or successfully appeal the FDA's and Health Canada's decision, competition, inability to achieve regulatory approval for our devices, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation, risks related to adverse business conditions, our dependence on key employees, competition for qualified personnel, the possible unavailability of financing as and if needed, and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company's 2024 Form 10-K filed with the Securities and Exchange Commission on March 31, 2025, and other reports and documents filed from time to time by us, which are available online at www.sec.gov.

CytoSorbents™

CytoSorbents at a Glance



- **Platform** blood purification technology for removing toxins and harmful substances from the blood
- **High margin** "razorblade" that we manufacture in U.S. - is "plug and play" into existing hospital blood pumps

CytoSorb

- Treatment of life-threatening conditions in the ICU and cardiac surgery
- Record core product sales of **$37.0 million** (TTM as of 9/30/25) and 71% gross margins
- E.U. Approved with **nearly 300,000** CytoSorb devices utilized cumulatively to date in 70+ countrie

DrugSorb ATR

- Investigational device to reduce the severity of perioperative bleeding during CABG surgery due to blood thinners
- **Two FDA Breakthrough Device Designations**
- Actively pursuing **regulatory approval in the US with new De Novo application, with a regulatory decision expected mid-2026, and potentially sooner**

- **Driving to cash flow breakeven in Q1 2026 and near-term profitability with a strengthened balance sheet as a key priority**

* CytoSorb and DrugSorb-ATR are not yet cleared or approved in the U.S. or Canada

CytoSorbents™

The Power of the Bead

Hemocompatible, highly porous polymer bead platform technology that act like tiny sponges to remove harmful substances from blood by pore capture, adsorption, and concentration



- Excellent removal of a broad range of substances from whole blood and plasma
- Solid state porous polymer chemistry that does not use ligands, antibodies, cells, or biologics
- 22 issued U.S. patents and multiple patents issued and pending worldwide
- Beneficiary of ~$50M in grants and non-dilutive funding from NIH, DARPA, DOD

CytoSorbents™

Products are “Plug and Play” Compatible

Compatible with Existing Blood Pump Infrastructure In Hospitals Today

Dialysis or CRRT
(Continuous Renal Replacement Therapy)



Hemoperfusion
(Standalone Treatment)



ECMO
(Extracorporeal Membrane Oxygenation)



CPB
(Cardiopulmonary Bypass)



CytoSorbents™

Expanding the Dimension of Blood Purification

CytoSorb is a powerful blood purification technology that removes a broad range of harmful substances that dialysis does not

CytoSorb works like the liver

Large Molecules and
Fat soluble substances

Cytokines
Inflammatory mediators
Bacterial toxins
Liver toxins
Proteins and peptides
Fat-soluble drugs

Dialysis works like the kidney

Small Molecules and
Water soluble substances

Urea, Ammonia
Electrolytes
Water
Water-soluble drugs

CytoSorb has 7 football fields of surface area to bind toxins compared to ¾ of a ping pong table for a dialyzer

CytoSorbents™

CytoSorb

Our Core Business

CytoSorb Controls Massive Inflammation - the Heart of Critical Illness

- Acute inflammation is the body's mechanism to fight injury and infection
- However, severe inflammation, driven by cytokine storm, can cause a chain reaction of problems that can end in organ failure and death



- Severe inflammation is the common thread amongst most critical illnesses and impacts up to 60% of patients in the ICU. Is directly correlated to increased severity of illness, organ failure, and mortality

CytoSorb controls deadly inflammation and has demonstrated the reversal or prevention of many of these complications

CytoSorbents™

Targets Deadly Conditions That Afflict Millions of People

Critical Care

Removes the "fuel to the fire" of massive uncontrolled inflammation that is often associated with organ failure and death

Sepsis

Surgical Complications



Influenza

Burn Injury



COVID-19



Cytokine Release Syndrome



Lung Injury



Liver Failure

Trauma

Pancreatitis

Cardiothoracic Surgery

Reduces inflammation and blood thinners, targeting reduction in complications of cardiac surgery like sepsis, bleeding, shock, and others

Life-threatening bleeding due to anti-thrombotic "blood thinners"



Infective Endocarditis



High Risk Procedures

CytoSorbents™

This is Why CytoSorb Continues To Grow in ICU applications



Sepsis, Septic Shock, Other Shock

Liver failure



Cytokine storm/ Cytokine release syndrome



Pancreatitis

Infectious diseases (flu, COVID-19, other)

Burn injury

Post-surgical complications Organ transplant



Neuroinflammation



Acute Respiratory Distress Syndrome (ARDS)

Trauma, Rhabdomyolysis



High risk surgical procedures, aortic surgery, Infective endocarditis

Drug overdose
Blood thinner toxicity



CytoSorb helps to treat critical illnesses where massive inflammation plays a dangerous role in 40-60% of patients in the ICU. Compare this to the only 10-15% of patients who require dialysis in the ICU

CytoSorbents™

Continue to Leverage Clinical Data



Voices around the world

CytoSorbents™

CytoSorbents is Leading a New Era in Sepsis Treatment

For more than a decade, CytoSorbents has collaborated with clinicians and scientists around the world to advance the treatment of sepsis and septic shock by complementing traditional antibiotics with the broad-spectrum capability of CytoSorb

Antibiotics treat the infection

CytoSorb treats the deadly inflammatory response by removing the “fuel to the fire” that causes a system crash

CytoSorbents™

CytoSorbents™

Working to save lives together.

Turning the Tide of Sepsis and Septic Shock:

Real World Insights with CytoSorb

September 10, 2025

Link to webinar replay: https://cyto.news/webinar-sepsis/sep10

The Opportunity of

DrugSorb™ ATR

CytoSorbents™

* *The DrugSorb-ATR system is an investigational device that is not yet cleared/approved by FDA, Health Canada, or by any other Global Regulatory Agency and is not commercially available for sale*

Blood Thinners Can Cause Serious Perioperative Bleeding
DrugSorb-ATR can help

- Millions of people are on blood thinners to reduce their risk of heart attack and stroke
- Acute heart attack patients commonly receive “super-aspirin” blood thinners like Brilinta® to improve clinical outcomes
- But Brilinta® (ticagrelor) can cause serious and potentially life-threatening bleeding in patients that need to undergo urgent coronary artery bypass graft (CABG) surgery
- Only drug washout for 3-5 days can reduce the risk of serious bleeding. However:
  - Frequently, surgery cannot wait - patients now risk major bleeding
  - Delaying surgery in a patient who is still having a heart attack risks complications like sudden death, and is expensive and an inefficient use of hospital resources
- DrugSorb-ATR is a Breakthrough Designated Device intended to solve this pervasive and serious unmet medical need in the U.S. and Canada that puts tens of thousands of patients at risk each year and addresses a >$1B market opportunity over time

CytoSorbents™

DrugSorb-ATR is an investigational medical device in the U.S. and Canada and is not yet cleared or approved.
Brilinta® is a trademark of AstraZeneca

Brilinta® and the Use Case for DrugSorb™ ATR

DrugSorb™ ATR



The ultimate goal of DrugSorb-ATR is to allow patients to get the critical surgery they need without delay, while reducing or preventing bleeding complications

CytoSorbents™

DrugSorb-ATR is De Novo Eligible

- U.S & Canadian randomized controlled STAR-T trial established DrugSorb-ATR as a De Novo 510(k) eligible device, DrugSorb-ATR must show that its probable benefits outweigh its probable risks to gain market clearance

- Our initial De Novo submission that was reviewed this year was denied primarily due to FDA's request for additional information to support efficacy and our proposed label indication. Most issues have now been resolved, with three important outcomes from our discussions with FDA

  1) FDA recommended a new De Novo submission to provide robust analyses of new real-world evidence demonstrating DrugSorb-ATR's effectiveness in clinical practice that were either not available with the first submission, or not eligible for inclusion in the prior review and appeal due to FDA rules

  2) FDA raised no safety concerns with DrugSorb-ATR, significantly reducing the "risk" side of the De Novo assessment. Under FDA Breakthrough Device, De Novo, and Least Burdensome guidelines, FDA has established a precedent to provide market approval for safe/low risk devices and allow post-market data collection (e.g. registry) to answer remaining questions on efficacy

  3) FDA indicated agreement that a new De Novo review would be limited to the remaining open items from the prior submission, which should streamline the process.

 DrugSorb-ATR is an investigational medical device in the U.S. and Canada and is not yet cleared or approved.

CytoSorbents™

FDA Regulatory Timeline

- On November 7, 2025, we filed a formal Pre-Submission Meeting Request with supporting documentation
- Anticipate a pre-submission meeting will be held in either late 2025 or early Q1 2026 to confirm FDA requirements for the new De Novo application
- Expect to file a new De Novo Filing in Q1 2026, that includes robust analyses of real-world evidence that FDA has not seen before
- Anticipate mid-2026 regulatory decision following a typical 150-day review process
- Review may be expedited as DrugSorb-ATR is still an FDA Breakthrough Device eligible for priority and interactive review

 DrugSorb-ATR is an investigational medical device in the U.S. and Canada and is not yet cleared or approved.

CytoSorbents™

Financial Performance

CytoSorbents™

CytoSorb Commercialization Focus

- We sell CytoSorb in more than 70 countries worldwide with nearly 300,000 treatments to date
- Sell Direct in Germany and 9 other countries, through Distributors and partners in the remainder

Estimated Revenue By Market



Revenue By Geography



* Switzerland, Austria, Poland, Netherlands, England, Wales, North Ireland, Scotland, Ireland

CytoSorbents™

Core Business Performance Summary

- Q3 2025 Revenue was $9.5M, a 10% increase vs $8.6M a year ago
  - Performance led by record sales in our distributor territories, and strong sales in our other direct markets
  - Aided by favorable currency exchange
  - Currently undergoing a restructuring of our German sales team and processes to drive a return to growth and more consistent financial performance in 2026
  - Gross margin remains solid at ~70%
- Strong balance sheet with $9.1M in cash (as of 9/30/25)
- Amended credit agreement provides additional $2.5M in cash and 6-month extension of interest only period to Jan 1, 2027

CytoSorbents™

Targeting Acceleration of Annual Revenue Growth



* 2022 and 2023 Core Product Sales were impacted by fall of the Euro to dollar compared to 2021.

** Trailing 12 months (as of 6/30/25)

Trailing 12-month revenue (as of 9/30/25) was $37.0M vs $33.8M in the comparable period a year ago

- Distributor/Partner sales: $15.6M (+14.4% growth)
- Direct Sales (outside Germany): $8.8M (+23.5% growth)
- Germany: $12.6M (-3.2% growth)

With Germany:	+9.4% sales growth
Without Germany:	+17.3% sales growth

Rest of business is healthy, with our focus on returning Germany to growth

CytoSorbents™

A Clear and Compelling Value Proposition

We believe we are significantly undervalued with a sound plan to build and maximize shareholder value

- ✓ CytoSorb is an established, international core business in critical care and cardiac surgery with $37M in high margin product sales and an excellent “razorblade” business model with expectations for strong future growth due to:
  - Significant critical care and cardiac surgery market opportunity worldwide, targeting major unmet medical needs
  - A commitment to bringing DrugSorb-ATR to the North American market with a near-term De Novo submission
  - Active measures to restore Germany back to growth
- ✓ Goal is to drive accelerated growth and drive the company to cash flow breakeven in Q1 2026 and future profitability

CytoSorbents™

CytoSorbents Corporation

NASDAQ: CTSO

Company Contact:
Dr. Phillip Chan
pchan@cytosorbents.com
www.cytosorbents.com